Shots:

• The US FDA has granted ODD to Prosetin for the treatment of ALS. ODD provides incentives for the development of drugs- biologics- and devices for diseases affecting 200-000 or fewer Americans
• By obtaining ODD- Prosetin is now eligible for benefits including up to 7yrs. of marketing exclusivity if it receives regulatory approval- exemption from FDA user fees- FDA assistance in clinical trial design- and tax credits for clinical research
• Prosetin is an oral- brain penetrant MAP4 kinase inhibitor- developed at Columbia University for the treatment of ALS

­ Ref: PRNewswire | Image: Twitter